Background and Aim
The preferred first-line antiretroviral
treatment (ART) regimen in South Africa contains dolutegravir (DTG), which was
introduced in the public health care system in 2019. DTG-based treatment
increases body weight, but the metabolic sequelae of weight gain due to DTG are
poorly understood. Because of the large burden of HIV, obesity, hypertension,
diabetes, and related micro- and macrovascular complications in South Africa,
the healthcare system is challenged, and there is a risk that it will be
further challenges as a consequence of the increased use of DTG-based
treatment. The overall aim of the project is to investigate the effects of a time-restricted
eating -based intervention on body weight and risk factors for T2D in men and
women with overweight/obesity living with HIV who have initiated DTG-based ART.
Period: The study runs from 01.09.2021 to 31.03.2025
Collaborators
University of Cape Town, University of Copenhagen, South African Medical
Research Council
Funding
EFSD